Abstract: The present invention is concerned with new 3,3-disubstituted indol-2-one derivatives of the general Formula (I). Compounds according to the invention are useful for the prophylaxis or treatment of the disorders of the central nervous system.

Abstract: The present invention is related to new 3,3-disubstituted indol-2-one derivatives of the general Formula (I). The new compounds are useful for the treatment or prophylaxis of the central nervous system, the gastrointestinal system or the cardiovascular system.

Abstract: The present invention is concerned with new 3,3-disubstituted indol-2-one derivatives of the general Formula (I), wherein R1 stands for hydrogen, halogen, alkyl having 1-7 carbon atom(s) or sulfonamido; R2 represents hydrogen or halogen; R3 denotes hydrogen, alkyl having 1-7 carbon atom(s) optionally carrying an aryl substituent or aryl optionally carrying one or two halogen substituent(s); R4 stands for alkyl having 1-7 carbon atom(s); R5 represents a group of the general Formula (II a) or (II b), wherein Q and W each represents nitrogen or CH; R6, R7 and R8 each stands for hydrogen, halogen, trifluoromethyl, alkyl or alkoxy having 1-7 carbon atom(s), or R6 and R7 together represent ethylenedioxy; m is 0, 1, or 2; a is a single, double or triple bond; n is 0, 1 or 2; and pharmaceutically acceptable acid addition salts thereof which are useful in the treatment or prophylaxis of diseases of the central nervous system, the gastrointestinal system and the cardiovascular system.

Abstract: The present invention is concerned with new indol-2-one derivatives of the general Formula (I). The new compounds are useful for the treatment or prevention of the disorders of the central nervous system or the cardiovascular system.

Abstract: The present invention relates to a new method of preparation of the polymorph form 1 of methyl (S)-(+)-(2-chlorophenyl)-2-(6,7-dihydro4H-thieno[3,2-c]pyridine-5-yl-acetate hydrogensulfate of the formula (I).

Abstract: The present invention relates to a new method of preparation of the polymorph form 1 of methyl (S)-(+)-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridine-5-yl-acetate hydrogensulfate of the formula (I).

Abstract: The invention refers to novel 2,3-benzodiazepine derivatives of formula (I) and pharmaceutical compositions containing the same as the active ingredient. The novel compounds antipasmodic, muscle relaxant and neuroprotective activities. In formula I; X represents a hydrogen atom, a chloro atom or a methoxy group; Y stands for a hydrogen atom or a halo atom; Z means a methyl group or a chloro atom; R is a C1-4 alkyl group or a group of the formula —NR1R2, wherein R1 and R2 represent, independently, a hydrogen atom, a C1-4 alkyl group, a C1-4 alkoxy group or a C3-6 cycloalkyl group.

Abstract: The invention relates to new crystalline forms I and II of (4R-cis)-6-[2-[3-phenyl-4-(phenyl-carbamoyl)-2-(4-fluoro-phenyl)-5-(1- methyl-ethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]dioxane-4-yl-acetic acid-tertiary butyl ester of the Formula (I) and a process for the preparation thereof.

Abstract: The invention relates to new piperidinyl-alkylamino-pyridazinone derivatives of the general Formula (I) (wherein R is hydrogen or C1-4-alkyl; one of X and Y stands for hydrogen and the other represents a group of the general Formula (II) Hal stands for halogen; and n is 1 or 2) and pharmaceutically acceptable acid addition salts thereof a process for the preparation thereof and pharmaceutical compositions comprising said compounds.

Abstract: The present invention relates to new crystalline forms I, II and III of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine hydrochloride, a process for the preparation thereof and pharmaceutical compositions containing the same. Said new polymorphic forms are useful as active ingredients for the treatment of psychotic conditions.

Abstract: The compounds of the general Formula I, wherein R1 stands for hydrogen or lower alkyl; one of symbols X and Y stands for hydrogen or halogen and the other represents a group of the general Formula II, R2 is hydrogen or lower alkyl; n is 1, 2 or 3; R3 is hydrogen, lower alkyl or aryl-lower alkyl; Z is -0-; or R3 and Z together with the intermediate atoms form piperazino ring; Q and W independently from each other stands for —CH? or —N?; and R4, R5 and R6 can be the same or different and stand for hydrogen, halogen, trifluoromethyl or lower alkoxy; or R4 and R5 together form an ethylenedioxy group) and pharmaceutically acceptable salts thereof can be used for the treatment or prophylaxis of malfunctions of memory and/or cognitive decline or prevention of decline of learning abilities.

Abstract: The invention refers to novel 2H-pyridazine-3-one derivatives of the formula I, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient. The novel compounds possess neuroleptic effect and can be used, primarily, for the treatment of schizophrenia. In formula I, R stands for a hydrogen atom or a C1-4, alkyl group, X and Y represent, independently, a hydrogen atom, a halogen atom or a group of the formula II, with the proviso that one of X and Y means always a group of the formula II, and then the other one stands for a hydrogen atom or a halogen atom, wherein in formula II n has a value of 1 or 2.

Abstract: The invention relates to new 2,3-benzodiazepine derivatives of general Formula (I), (wherein R1 stands for methyl, formyl, carboxy, cyano, —CH?NOH, —CH?NNHCONH2 or —NR5R6, wherein R5 and R6 independently from each other represent hydrogen or lower alkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s); R2 is nitro or amino; R3 stands for hydrogen, lower alkanoyl or CO—NR7R8, wherein R7 and R8 independently from each other stand for hydrogen, lower alkoxy, lower alkyl or lower cycloalkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s); R4 is hydrogen or lower alkyl; the dotted lines have the following meaning: if R3 and R4 are not present, the bond between positions C8 and C9 is a single bond and th

Abstract: The invention relates to new piperidinyl-alkylamino-pyridazinone derivatives of the general Formula (I) (wherein R is hydrogen or C1-4-alkyl; one of X and Y stands for hydrogen and the other represents a group of the general Formula (II) Hal stands for halogen; and n is 1 or 2) and pharmaceutically acceptable acid addition salts thereof a process for the preparation thereof and pharmaceutical compositions comprising said compounds. The compounds of the general Formula I exhibit anxiolytic effect and are useful in the treatment of anxiety.

Abstract: The invention relates to substituted alkylaminopyridazinone derivatives of the general Formula (I), (wherein R1 is hydrogen or alkyl having 1-4 carbon atoms; one of X and Y stands for hydrogen or halogen and the other represents a group of the general Formula (II), R2 is hydrogen or alkyl having 1-4 carbon atoms; n is 1, 2 or 3; R3 stands for hydrogen, alkyl having 1-4 carbon atoms or aryl-(C1-4 alkyl); Z stands for oxygen; or R3 and Z together with the groups placed between them form a piperazine ring; and R4 stands for hydrogen, halogen, trifluoromethyl or alkoxy having 1-4 carbon atoms) and pharmaceutically acceptable acid addition salts thereof. The invention compounds are useful in the treatment of anxiolytic conditions and cognitive disorders.

Abstract: The invention relates to crystalline forms I and II methyl-(S)-(+)-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2.c]pyridine-5-yl)-acetate hydrochloride of the Formula (I) and hydrates thereof, a process for the preparation thereof and pharmaceutical compositions containing the same. The new polymorphs according to the invention exhibit blood platelet aggregation inhibiting and antithrombotic effect.

Abstract: New substituted alkylaminopyridazinone derivatives of the general Formula (I), (wherein R1 is hydrogen or alkyl having 1-4 carbon atoms; X is hydrogen or halogen; R2 is hydrogen or alkyl having 1-4 carbon atoms; n is 1, 2 or 3; Q and W independently from each other stand for —N? or —CH?; and R4 and R5 independently from each other represent hydrogen, halogen, trifluoromethyl or alkoxy having 1-4 carbon atoms) and pharmaceutically acceptable acid addition salts thereof possess useful anxiolytic and cognition enhancing properties.

Abstract: The invention relates to the new crystalline form I 5-chloro-4-[3-[N-[2-(3,4-dimethoxy-phenyl)-ethyl]-N-methylamino]-propylamino]-3-[2H]-pyridazinone fumarate, a process for the preparation thereof, pharmaceutical compositions containing the same and the use of said new polymorph for the treatment of arrhythmia.

Abstract: The invention relates to new crystalline forms I and II of (4R-cis)-6-[2-[3-phenyl-4-(phenyl-carbamoyl)-2-(4-fluoro-phenyl)-5-(1-methyl-ethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]dioxane-4-yl-acetic acid-tertiary butyl ester of the Formula (I) and a process for the preparation thereof. The new polymorphs of the present invention are useful pharmaceutical intermediates which can be used in the preparation of the hydroxymethyl-glutaryl coenzyme (HMG-COA) reducing enzyme inhibitor having the INN (International Non-proprietory Name) atorvastatin.

Abstract: The invention relates to new substituted alkylaminopyridazinone derivatives of the general Formula (I), (wherein R1 is hydrogen or alkyl having 1-4 carbon atoms; one of X and Y stands for hydrogen or halogen and the other represents a group of the general Formula (II), R2 is hydrogen or alkyl having 1-4 carbon atoms; n is 1, 2 or 3; R3 stands for hydrogen, alkyl having 1-4 carbon atoms or aryl-(C1-4 alkyl); Z stands for oxygen; or R3 and Z together with the groups placed between them form a piperazine ring; and R4 stands for hydrogen, halogen, trifluoromethyl or alkoxy having 1-4 carbon atoms) and pharmaceutically acceptable acid addition salts thereof. The invention compounds are useful in the treatment of anxiolytic conditions and cognitive disorders.